| Description |
Acapatamab (AMG-160) is a half-life extended bispecific T cell engager (HLE BiTE), including an anti-PSMA binding domain and an anti-CD3 binding domain with Kd values of 14.8 nM and 22.4 nM for hPSMA and hCD3, respectively. Acapatamab can be used in research of cancer[1].
|
| Related Catalog |
|
| Target |
kd: 14.8 nM (hPSMA) and 22.4 nM (hCD3)[1]
|
| In Vitro |
Acapatamab (AMG-160; 0-10000 pM; 48 h) 诱导 T 细胞活化，T 细胞中 CD25、CD69、4-1BB和 PD-1 表达增加[1]。 Acapatamab (0-10000 pM; 48 h; T-cell) 诱导剂量依赖性细胞因子分泌，包括 IL2、IL4、IL6、IL10、IFNγ 和 TNFα[1]。 Acapatamab (0-10000 pM; 48 h) 诱导与 PBMC 共培养的前列腺特异性膜抗原 (PSMA) 阳性前列腺癌细胞系的有效裂解，EC50 值为 6-42 pM[1]。
|
| In Vivo |
Acapatamab (0.02-2 mg/kg; i.v.; 第 16, 23 和 31 天) 具有抗肿瘤活性，并抑制 NOD/SCID 小鼠 22Rv-1 CRPC 异种移植瘤的肿瘤生长[1]。 Animal Model: NOD/SCID mice with 22Rv-1 CRPC xenografts[1] Dosage: 0.02, 0.2, and 2 mg/kg Administration: Intravenous injection (days 16, 23, and 31) Result: Had antitumor activity against established CRPC tumors.
|
| References |
[1]. Deegen P, et, al. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 May 15;27(10):2928-2937.
|
